PPT-Peginterferon alfa-2a (

Pegasys Prepared by David Spach MD amp H Nina Kim MD Last Updated February 14 2014 Background and Dosing Peginterferon alfa2a Pegasys Peginterferon alfa2a Pegasys Summary. PRODUCT MONOGRAPH interferon alfa-2b Lyophilized Powder with Diluent10 million IU interferon alfa-2b/vial 18 million IU interferon alfa-2b/vial Ready-to-Use Solution 10 million IU interferon alfa-2b/v Alfa Laval is a leading global provider of specialized products and engineered solutions.. Our equipment, systems and services are dedicated to helping customers to optimize the performance of their processes. Time and time . Alfa Laval is a leading global provider of specialized products and engineered solutions. Our equipment, systems and services are dedicated to helping customers to optimize the performance of the Alfa Laval spiral heat exchangers Problem solvers for tough applications 2 Alfa Laval – spiral heat exchangers severe fouling. When it’s nally time for maintenance SHEs are considerably sa versus. . Interferon alfa-2b + Ribavirin . Phase 3. Treatment. . Naïve, Chronic HCV. Manns. . MP, et. al. Lancet. 2001;358:958-65. Peginterferon alfa-2b + Ribavirin . versus . Interferon alfa-2b + Ribavirin . Phase 3. Treatment. . Naïve, Chronic HCV. McHutchison. . JG, et al. N . Engl. J Med. 1998;339:1485-92.. I. nterferon . alfa-. 2b . +/- Ribavirin for Chronic HCV. Study . Outline. Study. -. . Randomized, double-blinded, placebo controlled, phase 3 trial. Using . SiPM. to readout Scintillating Fibers . What has been done for ALFA. The “Scintillating Fibers & . SiPM. ” status of the art. . ALFA. . SiPM. Collecting Information. Starting discussion. Flat versus Weight-Based Ribavirin Dosing. Phase . 3. Treatment. . Naïve, Chronic HCV. Jacobson IM, et. al. Hepatology. 2007;46:971-81.. *Weight-based . ribavirin. dosing: < 65 kg: 800 mg/. d. . or 3 . LONESTAR-2. Phase 2. Treatment. . Experienced. Lawitz. . E, et al. . Hepatology. . 2015:61:769-75.. Source: . Lawitz. E, et al. . Hepatology. . . 2015:61:769-75.. Sofosbuvir + . PEG + RBV . RBV . versus. Interferon alfa. -. 2a + RBV . ACTG 5071. Phase . 2. Treatment. . Naïve, Chronic HCV and HIV. Chung RT, . et. al. N . Engl. J Med. . 2004;351:451-9. . PEG alfa. -2a . + . RBV . versus. . PEG alfa-. 2a . versus. INF RBV . APRICOT STUDY. Phase 3. Treatment. . Naïve, Chronic HCV and HIV. Torriani. FJ, . et. al. N . Engl. J Med. . 2004;351:438-50. . PEG . . RBV . versus. . PEG . Richard . Dolinar. , MD. Endocrinologist, Chairman of the Alliance for Safe Biologic Medicines. Presented at the . Colorado . Biosimilars. . Educational Forum  . December . 6, . 2012. 2. The differences between Chemical Drugs and Biotech Medicines you . Editorial April 2018 Alfa Laval reserves the right to change specifications without prior notification. Smooth - running ballast water treatment with Alfa Laval PureBallast 3 Dowa Line, USA, Case s ID . : . DB00008 . Protein average . weight : . 60000.0000. . Half life : . Terminal half life is 80 hours (range 50 to 140 hours). . . Description. :. . Human interferon 2a, is a covalent conjugate of recombinant alfa-2a interferon with a single branched .